General surgery is undergoing a period of rapid transformation. Robotics, artificial intelligence, advanced imaging, digital technologies, and data-driven decision support are reshaping how procedures are planned, performed, and evaluated. As innovation accelerates, MedTech companies face increasing pressure to generate meaningful clinical evidence, demonstrate value to stakeholders, and bring new technologies to market efficiently.
With more than two decades of experience spanning clinical strategy, evidence generation, regulatory affairs, and commercialization, John McGuire has helped organizations navigate the complexities of surgical innovation. As IQVIA MedTech's Director of Clinical Affairs, General Surgery, he partners with clients developing next-generation surgical technologies, helping align clinical development, evidence generation, and commercialization strategies to accelerate adoption and improve patient outcomes.
We are seeing a convergence of medical technologies that have the potential to fundamentally change surgical care. Robotics, AI, advanced imaging, digital health platforms, and data analytics are creating opportunities to improve precision, consistency, and decision-making throughout the patient journey.
What is particularly exciting is that innovation is no longer focused solely on the procedure itself. Companies are increasingly looking across the entire care pathway, from patient selection and procedural planning to post-operative monitoring and long-term outcomes. The organizations that succeed will be those that can demonstrate measurable value across that broader continuum of care.
Surgical innovation often moves faster than traditional evidence-generation, outcomes, and payor models. While technologies are becoming increasingly sophisticated, companies still need to demonstrate that those innovations translate into meaningful patient and clinical outcomes.
The challenge is that outcomes are influenced by many variables, including surgeon experience, technique, patient characteristics, and site variability. Designing studies that capture real-world value while meeting regulatory and various stakeholder expectations is critical.
At the same time, organizations have more evidence-generation tools available than ever before, including real-world data, registries, digital endpoints, and post-market evidence strategies that complement traditional clinical studies.
One lesson has remained consistent throughout my career: clinical, regulatory, and commercial strategies must be in concert from the beginning.
Too often, organizations approach evidence generation solely through the lens of regulatory approval. While approval is critical, companies also need evidence that supports physician adoption, hospital decision-making, reimbursement, and long-term commercial success in the least burdensome manner possible.
The most successful programs establish these objectives early and create an integrated strategy that addresses stakeholder needs across the entire product lifecycle.
AI’s greatest value will come from its ability to transform large volumes of clinical and procedural data into actionable insights. Applications such as image analysis, surgical planning, workflow optimization, decision support, and outcome prediction all have significant potential.
However, long-term success will depend on demonstrating that these tools create meaningful clinical value, decision making, and improvement in patient outcomes. As with any innovation in healthcare, evidence, reliability, and trust will remain essential to adoption.
The greatest impact will come from technologies that streamline approaches, reduce variability in care and improve decision-making. While robotics will continue to advance, the future extends beyond robotic platforms themselves.
The integration of imaging, AI, navigation systems, predictive analytics, and connected data ecosystems will help surgeons make more informed decisions before, during, and after procedures. We are moving toward a future where technology increasingly supports consistency, personalization, and measurable improvements in patient outcomes.
Today’s surgical technologies require more than clinical and regulatory expertise alone. Success depends on effectively connecting evidence generation, reimbursement considerations, market access, and commercialization planning.
IQVIA MedTech brings together these capabilities across the product lifecycle, helping organizations develop integrated strategies that reduce risk, accelerate development timelines, and support successful adoption in an increasingly complex healthcare environment.
John McGuire’s perspective reflects a broader shift occurring across general surgery: the future belongs to technologies that can demonstrate measurable clinical value, integrate seamlessly into care pathways, and improve patient outcomes. Innovation succeeds when evidence, strategy, and commercialization are aligned from the start.
As advancements in robotics, artificial intelligence, imaging, and digital health continue to reshape surgical care, IQVIA MedTech helps innovators generate the evidence needed to move confidently from development to adoption, turning promising technologies into meaningful impact for patients and providers.
Related solutions
With IQVIA MedTech, you gain more than expertise—you gain a partner built for the medical device, diagnostics and digital health industry, dedicated to helping you thrive, every step of the way.
Our team works alongside your team, offering integrated medical device therapeutic expertise, technology, and processes to support a clearer understanding of the science, the patient, and the path forward.
IQVIA MedTech delivers lifecycle-aligned clinical research solutions to help generate the right evidence from early feasibility through post-market studies.
